<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861926</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0804-PR-0034</org_study_id>
    <nct_id>NCT00861926</nct_id>
  </id_info>
  <brief_title>Study Comparing Foster Efficacy Maintenance and Reliever Versus Foster Maintenance + Salbutamol Reliever in Asthmatics</brief_title>
  <official_title>48-week,Multinational,Randomized,Double-blind,2-parallel Groups,Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics &gt;=18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, multinational, multicentre, randomized, 2-arm parallel-group study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare efficacy of Foster as maintenance therapy plus additional inhalations as reliever&#xD;
      with Foster as maintenance plus salbutamol as reliever in asthmatics&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first severe asthma exacerbation</measure>
    <time_frame>At each clinic visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of severe asthma exacerbations Number of hospitalization Asthma symptoms Rescue medication LFTs</measure>
    <time_frame>At each clinic visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2079</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Beclometasone/formoterol (100/6 µg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventolin : salbutamol sulphate 100 µg per metered dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ventolin</intervention_name>
    <description>Ventolin : salbutamol sulfate 100µg</description>
    <arm_group_label>salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beclometasone /formoterol</intervention_name>
    <description>BDP 100µg/FF 6µg, 1 inhalation bid</description>
    <arm_group_label>Beclometasone/formoterol (100/6 µg)</arm_group_label>
    <other_name>Foster</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written signed and dated informed consent obtained.&#xD;
&#xD;
          -  Male or female patients aged ≥ 18 years.&#xD;
&#xD;
          -  A positive reversibility test&#xD;
&#xD;
          -  Patients who experienced at least one severe exacerbation in the 12 months before&#xD;
             entry (but not in the last month)&#xD;
&#xD;
          -  Using inhaled corticosteroids (ICS) in monotherapy or using ICS in a fixed or free&#xD;
             combination with long acting beta2 agonists (LABA) at a constant dose for two months&#xD;
             before screening visit&#xD;
&#xD;
          -  Not fully controlled asthmatics (which means partly controlled or/and uncontrolled&#xD;
             patients according to GINA guidelines 2007) in the last month before screening visit&#xD;
&#xD;
          -  Forced expiratory volume in the first second (FEV1) ≥ 60% of predicted for the patient&#xD;
             normal value.&#xD;
&#xD;
          -  Non smokers or ex-smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women. Women of child-bearing potential UNLESS they&#xD;
             meet the following definition of post-menopausal: 12 months of natural (spontaneous)&#xD;
             amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels &gt;40 mIU/mL or&#xD;
             are using one or more of acceptable methods of contraception&#xD;
&#xD;
          -  Body Mass Index (BMI) &gt; 34 kg/m2.&#xD;
&#xD;
          -  Patient with lower respiratory tract infections affecting the patient's asthma within&#xD;
             30 days of the screening visit.&#xD;
&#xD;
          -  Use of systemic steroids in the last month.&#xD;
&#xD;
          -  Patients with other lung diseases such as COPD, cystic fibrosis, interstitial lung&#xD;
             diseases or any other clinically or functionally significant lung disorder.&#xD;
&#xD;
          -  Patients who have an uncontrolled respiratory, haematological, immunologic, renal,&#xD;
             neurologic, hepatic, endocrinal or other disease.&#xD;
&#xD;
          -  Clinically relevant laboratory abnormalities&#xD;
&#xD;
          -  Patients who have an abnormal QTcF interval value&#xD;
&#xD;
          -  Intolerance or contra-indication to treatment with beta2-agonists and/or ICS or&#xD;
             allergy to any component of the study treatments.&#xD;
&#xD;
          -  Patients treated with slow-release corticosteroids in the 3 months prior to screening&#xD;
             visit.&#xD;
&#xD;
          -  Patients being treated with anti-IgE antibodies.&#xD;
&#xD;
          -  Patients treated with LABA or ICS/LABA fixed combination in the 24h before screening&#xD;
             visit&#xD;
&#xD;
          -  Severe asthma exacerbation in the last month before screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Papi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita degli Studi di Ferrara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pr Papi</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004671-22</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <results_reference>
    <citation>Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med. 2013 Mar;1(1):23-31. doi: 10.1016/S2213-2600(13)70012-2. Epub 2013 Mar 4.</citation>
    <PMID>24321801</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maintenance and Reliever Treatments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

